BioSpace News Archive

Drug Development

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR)

December 8, 2019
·
6 min read
Drug Development

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL

December 8, 2019
·
6 min read
Drug Development

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses

December 8, 2019
·
8 min read
Business

Company Profile for Jasper Therapeutics, Inc

Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning agents and therapeutics to allow for expanded use of curative hematopoietic stem cell transplants and gene therapies.

December 8, 2019
·
1 min read
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance

December 8, 2019
·
9 min read
Pharm Country

Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

Heavily pre-treated patients with chronic lymphocytic leukemia receiving liso-cel achieved durable complete responses, including undetectable minimal residual disease

December 8, 2019
·
11 min read
Genetown

BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma

December 8, 2019
·
16 min read
Drug Development

Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

US Phase 1 Trial Establishes Feasibility of Commercial “Process B” Vector/Cell Manufacturing in FA

December 8, 2019
·
8 min read
Policy

Public Health Notice: Outbreak of E. coli infections linked to Fresh Express brand Sunflower Crisp Chopped Salad Kits

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of E. coli infections occurring across five eastern provinces.

December 8, 2019
·
5 min read
Hitachi to Provide CNAO with Proton Therapy System

Hitachi, Ltd. has entered into an agreement to provide Centro Nazionale di Adroterapia Oncologica with its proton therapy system.

December 8, 2019
·
2 min read